Hepatitis C Virus Linked to Diabetes in Liver Transplant Recipients

Research published in the Liver Transplantation journal suggests that hepatitis C virus (HCV) infection may trigger diabetes in liver transplant recipients. A cohort of 555 liver transplant patients without pre-existing diabetes was followed for a median duration of 5 years, with 37.7% developing de novo diabetes. The study found that HCV infection was a significant predictor of persistent diabetes, with 14% of HCV-infected patients developing this condition. Older age and the use of tacrolimus were also identified as independent predictors of persistent diabetes.

Key Takeaways:

• De novo diabetes developed in 37.7% of liver transplant recipients without pre-existing diabetes, with 28.3% experiencing transient diabetes and 9.4% experiencing persistent diabetes.
• HCV infection was predictive of persistent diabetes (p=0.02) but not transient diabetes.
• Older age (p=0.03) and tacrolimus use (p=0.02) were also independent predictors of persistent diabetes.
• De novo diabetes is common in transplant recipients, with HCV infection being one of the most important risk factors for persistent diabetes.
• The study highlights the need for close monitoring and management of diabetic patients after liver transplantation, particularly those with HCV infection.

Statistics:

• 555 liver transplant recipients were included in the study.
• 37.7% of patients developed de novo diabetes, with 28.3% experiencing transient diabetes and 9.4% experiencing persistent diabetes.
• 26% of HCV-infected transplant recipients developed transient diabetes, while 14% developed persistent diabetes.
• The median duration of follow-up was 5 years.
• The study was conducted at 3 U.S. centers between 1990 and 1994.

Sources:

• Khalili M, et al. New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transplant, 2004;10(3):349-355.